Isotopia Molecular Imaging products

Prostate cancer is one of the leading causes of morbidity and mortality in men in the western world, and the second most common cancer in men worldwide.  Imaging of the prostate-specific membrane antigen (PSMA) has become an essential tool for managing patients with recurrent prostate cancer and 68Ga PSMA-11 is one of the most frequently employed radiopharmaceuticals.

Lutetium-177 (Lu-177) is being widely used as a promising radionuclide for targeted therapy and is emerging as a game-changing theranostic isotope for the treatment of neuroendocrine tumors, metastatic castration-resistant prostate cancer (mCRPC) along with its development for new carrier molecules that can provide selective targeting for tumor sites.